Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CHOEP-14 + Rituximab With CNS Prophylaxis in DLBCL/FL Grade III
NCT01502982Phase 2Completed
- Sponsor
- Nordic Lymphoma Group
- Start
- Nov 2004
- Primary completion
- Dec 2013
- Modality
- Monoclonal Antibodies, DNA Intercalators/Alkylators, Orthosteric Ligands
- Countries
- 4
01
Overview
A Phase 2 trial of rituximab, cyclophosphamide, doxorubicin, etoposide, vincristine in diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), sponsored by Nordic Lymphoma Group. Started Nov 2004; status: completed.
02
Drugs
rituximabcyclophosphamidedoxorubicinetoposidevincristine
03
Conditions
diffuse large B-cell lymphoma (DLBCL)follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01502982.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01502982.